A therapeutic approach involving not only AXL inhibition, but pan-TAM RTK inhibition may therefore help to prevent, or at least delay, resistance to PI3K inhibitors and improve outcomes for HNSCC patients. This evidence concerns the gene AXL and head and neck squamous cell carcinoma.